ReviewJournal of clinical medicine2026

Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer.

Marisa Rosso et al.PubMed ↗Publisher ↗

No numbers read from the abstract.